Sotac Pharmaceuticals

Sotac Pharmaceuticals Debt/EBITDA

The Total Debt to EBITDA Ratio of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 25, 2026 is 3.20. In the previous year, Total Debt to EBITDA Ratio was 3.01 — a change of 6.48% (higher).

Debt/EBITDA

3.20

YoY

6.48%

Last updated:

Total Debt to EBITDA Ratio of Sotac Pharmaceuticals is 2025 3.20 . Total Debt to EBITDA Ratio of Sotac Pharmaceuticals was 2024 3.01 . It decreases by 6.48% higher compared to the previous year.

The Sotac Pharmaceuticals Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2020
7.22 INR
Jan 1, 2021
11.77 INR
Jan 1, 2022
0.93 INR
Jan 1, 2024
3.01 INR
Jan 1, 2025
3.20 INR
The Sotac Pharmaceuticals Debt/EBITDA history
YEARDebt/EBITDAYoY
3.20+6.48%
3.01+224.42%
0.93-92.13%
11.77+63.05%
7.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Total Debt to EBITDA Ratio of Sotac Pharmaceuticals is 3.20 in 2025.

Total Debt to EBITDA Ratio of Sotac Pharmaceuticals changed from 3.01 to 3.20, representing a 6.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Sotac Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Sotac Pharmaceuticals

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Sotac Pharmaceuticals